413 related articles for article (PubMed ID: 24037760)
1. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD
J Pathol; 2013 Dec; 231(4):413-23. PubMed ID: 24037760
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a gene expression tumour classifier for cancer of unknown primary.
Tothill RW; Shi F; Paiman L; Bedo J; Kowalczyk A; Mileshkin L; Buela E; Klupacs R; Bowtell D; Byron K
Pathology; 2015 Jan; 47(1):7-12. PubMed ID: 25485653
[TBL] [Abstract][Full Text] [Related]
3. Massively parallel sequencing of ataxia genes after array-based enrichment.
Hoischen A; Gilissen C; Arts P; Wieskamp N; van der Vliet W; Vermeer S; Steehouwer M; de Vries P; Meijer R; Seiqueros J; Knoers NV; Buckley MF; Scheffer H; Veltman JA
Hum Mutat; 2010 Apr; 31(4):494-9. PubMed ID: 20151403
[TBL] [Abstract][Full Text] [Related]
4. Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing.
Won HH; Scott SN; Brannon AR; Shah RH; Berger MF
J Vis Exp; 2013 Oct; (80):e50710. PubMed ID: 24192750
[TBL] [Abstract][Full Text] [Related]
5. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin.
Tothill RW; Kowalczyk A; Rischin D; Bousioutas A; Haviv I; van Laar RK; Waring PM; Zalcberg J; Ward R; Biankin AV; Sutherland RL; Henshall SM; Fong K; Pollack JR; Bowtell DD; Holloway AJ
Cancer Res; 2005 May; 65(10):4031-40. PubMed ID: 15899792
[TBL] [Abstract][Full Text] [Related]
6. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
Andersson C; Fagman H; Hansson M; Enlund F
Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
[TBL] [Abstract][Full Text] [Related]
7. The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review.
Lorkowski SW; Dermawan JK; Rubin BP
Virchows Arch; 2024 Feb; 484(2):369-375. PubMed ID: 37999736
[TBL] [Abstract][Full Text] [Related]
8. Oligonucleotide probe array for p53 gene alteration analysis in DNA from formalin-fixed paraffin-embedded breast cancer tissues.
Lumachi F; Marino F; Varotto S; Basso U
Ann N Y Acad Sci; 2009 Sep; 1175():89-92. PubMed ID: 19796081
[TBL] [Abstract][Full Text] [Related]
9. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.
Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A
Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691
[TBL] [Abstract][Full Text] [Related]
10. Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study.
Tabone T; Abuhusain HJ; Nowak AK; ; Erber WN; McDonald KL
J Clin Pathol; 2014 Jul; 67(7):550-5. PubMed ID: 24695838
[TBL] [Abstract][Full Text] [Related]
11. Regional biases in mutation screening due to intratumoural heterogeneity of prostate cancer.
Kim TM; Jung SH; Baek IP; Lee SH; Choi YJ; Lee JY; Chung YJ; Lee SH
J Pathol; 2014 Aug; 233(4):425-35. PubMed ID: 24870262
[TBL] [Abstract][Full Text] [Related]
12. Efficient identification of miRNAs for classification of tumor origin.
Søkilde R; Vincent M; Møller AK; Hansen A; Høiby PE; Blondal T; Nielsen BS; Daugaard G; Møller S; Litman T
J Mol Diagn; 2014 Jan; 16(1):106-15. PubMed ID: 24211363
[TBL] [Abstract][Full Text] [Related]
13. Genetic characterisation of molecular targets in carcinoma of unknown primary.
Clynick B; Dessauvagie B; Sterrett G; Harvey NT; Allcock RJN; Saunders C; Erber W; Meehan K
J Transl Med; 2018 Jul; 16(1):185. PubMed ID: 29973234
[TBL] [Abstract][Full Text] [Related]
14. Molecular driver alterations and their clinical relevance in cancer of unknown primary site.
Löffler H; Pfarr N; Kriegsmann M; Endris V; Hielscher T; Lohneis P; Folprecht G; Stenzinger A; Dietel M; Weichert W; Krämer A
Oncotarget; 2016 Jul; 7(28):44322-44329. PubMed ID: 27322425
[TBL] [Abstract][Full Text] [Related]
15. Massively parallel DNA sequencing from routinely processed cytological smears.
Piqueret-Stephan L; Marcaillou C; Reyes C; Honoré A; Letexier M; Gentien D; Droin N; Lacroix L; Scoazec JY; Vielh P
Cancer Cytopathol; 2016 Apr; 124(4):241-53. PubMed ID: 26505273
[TBL] [Abstract][Full Text] [Related]
16. Deep sequencing in cancer research.
Yoshida K; Sanada M; Ogawa S
Jpn J Clin Oncol; 2013 Feb; 43(2):110-5. PubMed ID: 23225907
[TBL] [Abstract][Full Text] [Related]
17. A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.
Posner A; Prall OW; Sivakumaran T; Etemadamoghadam D; Thio N; Pattison A; Balachander S; Fisher K; Webb S; Wood C; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Wright G; Williams S; George J; Hicks RJ; Boussioutas A; Gill AJ; Solomon BJ; Xu H; Fellowes A; Fox SB; Schofield P; Bowtell D; Mileshkin L; Tothill RW
J Pathol; 2023 Jan; 259(1):81-92. PubMed ID: 36287571
[TBL] [Abstract][Full Text] [Related]
18. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with
Gröschel S; Bommer M; Hutter B; Budczies J; Bonekamp D; Heining C; Horak P; Fröhlich M; Uhrig S; Hübschmann D; Geörg C; Richter D; Pfarr N; Pfütze K; Wolf S; Schirmacher P; Jäger D; von Kalle C; Brors B; Glimm H; Weichert W; Stenzinger A; Fröhling S
Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001180. PubMed ID: 27900363
[TBL] [Abstract][Full Text] [Related]
19. Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test.
Monzon FA; Medeiros F; Lyons-Weiler M; Henner WD
Diagn Pathol; 2010 Jan; 5():3. PubMed ID: 20205775
[TBL] [Abstract][Full Text] [Related]
20. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary.
Varadhachary GR; Spector Y; Abbruzzese JL; Rosenwald S; Wang H; Aharonov R; Carlson HR; Cohen D; Karanth S; Macinskas J; Lenzi R; Chajut A; Edmonston TB; Raber MN
Clin Cancer Res; 2011 Jun; 17(12):4063-70. PubMed ID: 21531815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
